News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand [Yahoo! Finance]

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) had its price target lowered by analysts at Ascendiant Capital Markets from $8.00 to $0.85. They now have a "buy" rating on the stock.

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Form DEFA14A NovaBay Pharmaceuticals,

Form DEFA14A NovaBay Pharmaceuticals,

Form DEFA14A NovaBay Pharmaceuticals,

Form DEFA14A NovaBay Pharmaceuticals,

Form SC 13G/A NovaBay Pharmaceuticals, Filed by: Hudson Bay Capital Management LP

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}